Tonix Pharma ( (TNXP) ) has provided an announcement.
On September 16, 2024, the Company revealed that its TNX-801 vaccine candidate for mpox is in sync with the World Health Organization’s ideal product criteria, promising single-dose effectiveness, ease of administration, and ambient temperature stability. This announcement indicates significant progress in the development of a vaccine that could be effective even for immunocompromised individuals, potentially positioning the company favorably in the market. However, the statement includes forward-looking projections, cautioning investors about the uncertainties and risks that could impact the actual outcomes compared to the optimistic expectations.
Learn more about TNXP stock on TipRanks’ Stock Analysis page.
